BR112015019564A2 - tratamento de esclerose múltipla com laquinimod - Google Patents

tratamento de esclerose múltipla com laquinimod

Info

Publication number
BR112015019564A2
BR112015019564A2 BR112015019564A BR112015019564A BR112015019564A2 BR 112015019564 A2 BR112015019564 A2 BR 112015019564A2 BR 112015019564 A BR112015019564 A BR 112015019564A BR 112015019564 A BR112015019564 A BR 112015019564A BR 112015019564 A2 BR112015019564 A2 BR 112015019564A2
Authority
BR
Brazil
Prior art keywords
laquinimod
multiple sclerosis
human subject
treatment
sclerosis treatment
Prior art date
Application number
BR112015019564A
Other languages
English (en)
Inventor
Bar-Zohar Dan
Sorani Ella
Hayardeny Liat
Tarcic Nora
Gorfine Tali
Knappertz Volker
Gilgun Sherki Yossi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51351655&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015019564(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR112015019564A2 publication Critical patent/BR112015019564A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

resumo tratamento de esclerose múltipla com laquinimod esta invenção fornece um método para tratar um indivíduo humano que sofra de uma forma progressiva da esclerose múltipla, que compreende periodicamente a administração ao sujeito humano de uma quantidade de laquinimod eficaz para tratar o indivíduo humano. esta invenção também fornece laquinimod para utilização no tratamento de um sujeito humano que sofra de uma forma progressiva da esclerose múltipla. esta invenção proporciona ainda composições farmacêuticas e pacotes que compreendem uma quantidade eficaz de laquinimod para o tratamento de uma forma progressiva da esclerose múltipla.
BR112015019564A 2013-02-15 2014-02-13 tratamento de esclerose múltipla com laquinimod BR112015019564A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361765394P 2013-02-15 2013-02-15
US201361911106P 2013-12-03 2013-12-03
PCT/US2014/016278 WO2014127139A1 (en) 2013-02-15 2014-02-13 Treatment of multiple sclerosis with laquinimod

Publications (1)

Publication Number Publication Date
BR112015019564A2 true BR112015019564A2 (pt) 2017-07-18

Family

ID=51351655

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015019564A BR112015019564A2 (pt) 2013-02-15 2014-02-13 tratamento de esclerose múltipla com laquinimod

Country Status (18)

Country Link
US (2) US20140235670A1 (pt)
EP (1) EP2956137A4 (pt)
JP (1) JP2016510343A (pt)
KR (1) KR20150119227A (pt)
CN (1) CN105163737A (pt)
AU (1) AU2014216199A1 (pt)
BR (1) BR112015019564A2 (pt)
CA (1) CA2900503A1 (pt)
CL (1) CL2015002181A1 (pt)
EA (1) EA201591507A1 (pt)
HK (2) HK1218251A1 (pt)
IL (1) IL240014A0 (pt)
MX (1) MX2015010296A (pt)
PE (1) PE20151526A1 (pt)
SG (1) SG11201505818WA (pt)
TW (1) TW201442709A (pt)
UY (1) UY35328A (pt)
WO (1) WO2014127139A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014018485A8 (pt) 2012-02-03 2017-07-11 Teva Pharma Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途
CN106573014A (zh) * 2014-04-29 2017-04-19 梯瓦制药工业有限公司 用于治疗具有高残疾状况的复发‑缓解型多发性硬化症(rrms)的患者的拉喹莫德
MX2017004808A (es) 2014-10-16 2017-07-26 Novartis Ag Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
US10091217B2 (en) 2016-06-21 2018-10-02 Logrhythm, Inc. Risk based priority processing of data
US11167003B2 (en) * 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
ES2377149T3 (es) * 2006-06-12 2012-03-22 Teva Pharmaceutical Industries Limited Preparaciones de laquinimod estables
BRPI0814624A2 (pt) * 2007-07-11 2015-01-27 Medicinova Inc Tratamento de doença neurodegenerativa progresiva com ibudilaste
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CA2747235C (en) * 2008-12-11 2021-02-09 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
RS54328B1 (en) * 2009-06-19 2016-02-29 Teva Pharmaceutical Industries Ltd. MULTIPLE TREATMENT OF LAKVINIMOD SCLEROSIS
EA201390827A1 (ru) * 2010-12-07 2013-12-30 Тева Фармасьютикал Индастриз Лтд. Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом
JP2014521659A (ja) * 2011-07-28 2014-08-28 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途
US20140107154A1 (en) * 2012-10-12 2014-04-17 Teva Pharmaceutical Industries, Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
CN106573014A (zh) * 2014-04-29 2017-04-19 梯瓦制药工业有限公司 用于治疗具有高残疾状况的复发‑缓解型多发性硬化症(rrms)的患者的拉喹莫德

Also Published As

Publication number Publication date
PE20151526A1 (es) 2015-11-20
US20140235670A1 (en) 2014-08-21
CN105163737A (zh) 2015-12-16
HK1218251A1 (zh) 2017-02-10
EP2956137A4 (en) 2016-08-03
MX2015010296A (es) 2016-05-05
UY35328A (es) 2014-09-30
JP2016510343A (ja) 2016-04-07
SG11201505818WA (en) 2015-08-28
CA2900503A1 (en) 2014-08-21
HK1218254A1 (zh) 2017-02-10
AU2014216199A1 (en) 2015-09-03
US20180064702A1 (en) 2018-03-08
WO2014127139A1 (en) 2014-08-21
EA201591507A1 (ru) 2015-12-30
KR20150119227A (ko) 2015-10-23
CL2015002181A1 (es) 2016-06-03
IL240014A0 (en) 2015-09-24
TW201442709A (zh) 2014-11-16
EP2956137A1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
BR112014028017A2 (pt) composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
BR112016020618A8 (pt) oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX2019002190A (es) Uso de pridopidina para tratar distonías.
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
MX2019003069A (es) Uso de pridopidina para tratar el sindrome de rett.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
BR112018002763A2 (pt) método para cicatrização de ferimentos
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
BR112015023463A2 (pt) uso de sedoeptulose para prevenção ou tratamento de inflamação
BR112016006582A2 (pt) terapia combinada laquinimod para o tratamento da esclerose múltipla
BR112013023703A2 (pt) composição tópicas que compreendem diamino oxidase para o tratamento ou prevenção de doenças associadas a altos níveis de histamina que envolvem um aumento da dor
PH12020500472A1 (en) Autotaxin inhibitor compounds
AR094809A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2501 DE 11/12/2018.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI